GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (HKSE:01548) » Definitions » Cash Flow from Investing

Genscript Biotech (HKSE:01548) Cash Flow from Investing : HK$-2,804 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Genscript Biotech Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the six months ended in Dec. 2023, Genscript Biotech spent HK$574 Mil on purchasing property, plant, equipment. It gained HK$0 Mil from selling property, plant, and equipment. It spent HK$-0 Mil on purchasing business. It gained HK$0 Mil from selling business. It spent HK$37,013 Mil on purchasing investments. It gained HK$38,758 Mil from selling investments. It paid HK$25Mil for net Intangibles purchase and sale. And it paid HK$391 Mil for other investing activities. In all, Genscript Biotech gained HK$756 Mil on investment activities in financial market and operating subsidiaries for the six months ended in Dec. 2023.


Genscript Biotech Cash Flow from Investing Historical Data

The historical data trend for Genscript Biotech's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech Cash Flow from Investing Chart

Genscript Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,628.28 -776.48 -1,657.66 -3,451.24 -2,793.78

Genscript Biotech Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -340.27 -2,643.81 -828.55 -3,560.44 756.11

Genscript Biotech Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Genscript Biotech's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Genscript Biotech's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-2,804 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genscript Biotech  (HKSE:01548) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Genscript Biotech's purchase of property, plant, equipment for the six months ended in Dec. 2023 was HK$-574 Mil. It means Genscript Biotech spent HK$574 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Genscript Biotech's sale of property, plant, equipment for the six months ended in Dec. 2023 was HK$0 Mil. It means Genscript Biotech gained HK$0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Genscript Biotech's purchase of business for the six months ended in Dec. 2023 was HK$0 Mil. It means Genscript Biotech spent HK$-0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Genscript Biotech's sale of business for the six months ended in Dec. 2023 was HK$0 Mil. It means Genscript Biotech gained HK$0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Genscript Biotech's purchase of investment for the six months ended in Dec. 2023 was HK$-37,013 Mil. It means Genscript Biotech spent {stock_data.stock.currency_symbol}}37,013 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Genscript Biotech's sale of investment for the six months ended in Dec. 2023 was HK$38,758 Mil. It means Genscript Biotech gained HK$38,758 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Genscript Biotech's net Intangibles purchase and sale for the six months ended in Dec. 2023 was HK$-25 Mil. It means Genscript Biotech paid HK$25 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Genscript Biotech's cash from discontinued investing activities for the six months ended in Dec. 2023 was 0 Mil. It means Genscript Biotech paid HK$0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Genscript Biotech's cash from other investing activities for the six months ended in Dec. 2023 was HK$-391 Mil. It means Genscript Biotech paid HK$391 Mil for other investing activities.


Genscript Biotech Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Genscript Biotech (HKSE:01548) Business Description

Traded in Other Exchanges
Address
No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100
GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.
Executives
Wang Luquan 2401 A concert party to an agreement to buy shares
Wang Ye 2101 Beneficial owner
Zhang Fangliang 2401 A concert party to an agreement to buy shares
Huang Lili 2202 Interest of your spouse
Hu Zhiyong 2201 Interest of corporation controlled by you
Jin Weihong 2201 Interest of corporation controlled by you
Genscript Corporation 2101 Beneficial owner
Hillhouse Fund V, L.p. 2201 Interest of corporation controlled by you
Hillhouse Investment Management V, Ltd. 2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd. 2102 Investment manager
Gns Holdings Limited 2101 Beneficial owner
Hillhouse Capital Management V, Ltd. 2201 Interest of corporation controlled by you
Hillhouse Capital Management, Ltd. 2102 Investment manager

Genscript Biotech (HKSE:01548) Headlines

No Headlines